

Andrew Rawstron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7563330/publications.pdf>

Version: 2024-02-01

110
papers

8,617
citations

70961

41
h-index

43802

91
g-index

112
all docs

112
docs citations

112
times ranked

6510
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2008, 359, 575-583. | 13.9 | 518 |
| 2 | Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2017, 3, 28. | 3.4 | 405 |
| 3 | Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival. <i>Journal of Clinical Oncology</i> , 2005, 23, 2971-2979. | 0.8 | 380 |
| 4 | Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2540-2547. | 0.8 | 372 |
| 5 | Diagnostic criteria for monoclonal B-cell lymphocytosis. <i>British Journal of Haematology</i> , 2005, 130, 325-332. | 1.2 | 360 |
| 6 | International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. <i>Leukemia</i> , 2007, 21, 956-964. | 3.3 | 351 |
| 7 | Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. <i>Blood</i> , 2002, 100, 635-639. | 0.6 | 305 |
| 8 | Human peripheral blood B-cell compartments: A crossroad in B-cell traffic. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S47-60. | 0.7 | 258 |
| 9 | Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. <i>Blood</i> , 2001, 98, 29-35. | 0.6 | 249 |
| 10 | Response assessment in Waldenström macroglobulinaemia: update from the 6th International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176. | 1.2 | 226 |
| 11 | Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. <i>Blood</i> , 2002, 100, 2289-2290. | 0.6 | 207 |
| 12 | A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. <i>Leukemia</i> , 2016, 30, 929-936. | 3.3 | 200 |
| 13 | Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729. | 0.8 | 197 |
| 14 | Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. <i>Blood</i> , 2002, 100, 3095-3100. | 0.6 | 194 |
| 15 | Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. <i>Leukemia</i> , 2010, 24, 512-520. | 3.3 | 193 |
| 16 | Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2993-2999. | 6.7 | 187 |
| 17 | Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 2245-2247. | 0.6 | 184 |
| 18 | Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. <i>Leukemia</i> , 2013, 27, 142-149. | 3.3 | 176 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. <i>Blood</i> , 2004, 104, 948-955. | 0.6 | 175 |
| 20 | Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. <i>British Journal of Haematology</i> , 1997, 97, 46-55. | 1.2 | 165 |
| 21 | Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. <i>Blood</i> , 2015, 125, 1932-1935. | 0.6 | 163 |
| 22 | Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1647-1655. | 0.8 | 152 |
| 23 | Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 31-39. | 0.7 | 144 |
| 24 | Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 121-128. | 0.7 | 133 |
| 25 | In Vitro Generation of Long-lived Human Plasma Cells. <i>Journal of Immunology</i> , 2012, 189, 5773-5785. | 0.4 | 111 |
| 26 | Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1236-1241. | 0.8 | 109 |
| 27 | Minimal residual disease is an independent predictor for 10-year survival in CLL. <i>Blood</i> , 2016, 128, 2770-2773. | 0.6 | 106 |
| 28 | The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. <i>British Journal of Haematology</i> , 2001, 112, 814-819. | 1.2 | 103 |
| 29 | Different biology and clinical outcome according to the absolute numbers of clonal B cells in monoclonal B cell lymphocytosis (MBL). <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S19-23. | 0.7 | 86 |
| 30 | Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. <i>Blood</i> , 2013, 121, 4521-4528. | 0.6 | 81 |
| 31 | The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. <i>Blood</i> , 2000, 96, 3880-3886. | 0.6 | 78 |
| 32 | Overview of monoclonal B-cell lymphocytosis. <i>British Journal of Haematology</i> , 2007, 139, 701-708. | 1.2 | 72 |
| 33 | IgM myeloma: a rare entity characterized by a CD20 ⁺ CD56 ⁺ CD117 ⁺ immunophenotype and the t(11;14). <i>British Journal of Haematology</i> , 2008, 140, 547-551. | 1.2 | 66 |
| 34 | The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. <i>British Journal of Haematology</i> , 1999, 107, 148-153. | 1.2 | 64 |
| 35 | Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. <i>Blood</i> , 2004, 103, 2027-2031. | 0.6 | 64 |
| 36 | Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA&ENCI roundtable symposium. <i>American Journal of Hematology</i> , 2014, 89, 1159-1160. | 2.0 | 52 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 53-55. | 1.4 | 48 |
| 38 | Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. <i>Blood</i> , 2014, 124, 1296-1299. | 0.6 | 48 |
| 39 | Assessment of IgH PCR strategies in multiple myeloma.. <i>Journal of Clinical Pathology</i> , 1996, 49, 672-675. | 1.0 | 44 |
| 40 | Monoclonal B-cell lymphocytosis. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 430-439. | 0.9 | 44 |
| 41 | Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. <i>Leukemia</i> , 2006, 20, 2102-2110. | 3.3 | 43 |
| 42 | Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. <i>Blood</i> , 2010, 116, 5957-5960. | 0.6 | 42 |
| 43 | Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. <i>Haematologica</i> , 2016, 101, e69-e71. | 1.7 | 41 |
| 44 | Prevalence of monoclonal B-cell lymphocytosis: A systematic review. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S10-8. | 0.7 | 40 |
| 45 | Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. <i>Journal of Immunology</i> , 2017, 198, 4618-4628. | 0.4 | 40 |
| 46 | Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072. | 3.3 | 40 |
| 47 | A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. <i>Leukemia</i> , 2007, 21, 2046-2049. | 3.3 | 39 |
| 48 | A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 152, 570-578. | 1.2 | 38 |
| 49 | B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. <i>British Journal of Haematology</i> , 2007, 139, 600-604. | 1.2 | 35 |
| 50 | Assessment of minimal residual disease in myeloma and the need for a consensus approach. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 21-25. | 0.7 | 35 |
| 51 | Monoclonal B-cell lymphocytosis (MBL) in CLL families: substantial increase in relative risk for young adults. <i>Leukemia</i> , 2006, 20, 728-729. | 3.3 | 33 |
| 52 | Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 640-648. | 1.2 | 33 |
| 53 | The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 724-729. | 1.2 | 32 |
| 54 | Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. <i>Trials</i> , 2017, 18, 387. | 0.7 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | CD52 Expression in Waldenström's Macroglobulinemia: Implications for Alemtuzumab Therapy and Response Assessment. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 278-281. | 2.1 | 29 |
| 56 | Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. <i>Journal of Clinical Oncology</i> , 2022, 40, 2889-2900. | 0.8 | 29 |
| 57 | Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. <i>Leukemia</i> , 2017, 31, 2085-2093. | 3.3 | 27 |
| 58 | Isotype class switching and the pathogenesis of multiple myeloma. <i>Hematological Oncology</i> , 2002, 20, 75-85. | 0.8 | 25 |
| 59 | Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S42-6. | 0.7 | 25 |
| 60 | Immunophenotyping of Plasma Cells. <i>Current Protocols in Cytometry</i> , 2006, 36, Unit6.23. | 3.7 | 24 |
| 61 | Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. <i>Leukemia</i> , 2017, 31, 2416-2425. | 3.3 | 24 |
| 62 | Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 61-69. | 0.7 | 20 |
| 63 | Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 54-60. | 0.7 | 20 |
| 64 | Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients. <i>Seminars in Hematology</i> , 2004, 41, 192-200. | 1.8 | 19 |
| 65 | Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice. <i>British Journal of Haematology</i> , 2005, 128, 732-733. | 1.2 | 19 |
| 66 | Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. <i>Leukemia</i> , 2018, 32, 1307-1316. | 3.3 | 19 |
| 67 | Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 35-44. | 1.2 | 18 |
| 68 | Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. <i>Blood</i> , 2020, 135, 411-428. | 0.6 | 17 |
| 69 | Monoclonal B Cell Lymphocytosis—What Does It Really Mean?. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 52-59. | 1.2 | 16 |
| 70 | Minimal residual disease assessment in chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 499-512. | 0.7 | 15 |
| 71 | Occult B-cell lymphoproliferative disorders. <i>Histopathology</i> , 2011, 58, 81-89. | 1.6 | 14 |
| 72 | Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. <i>Health Technology Assessment</i> , 2017, 21, 1-374. | 1.3 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from <sc>NCRN CLL</sc>207: a phase II</sc> trial assessing alemtuzumab consolidation. British Journal of Haematology, 2017, 176, 573-582. | 1.2 | 13 |
| 74 | Immunophenotypic and DNA Genotypic Analysis of T-Cell and NK-Cell Subpopulations in Patients with B-Cell Chronic Lymphocytic Leukaemia (B-CLL). Leukemia and Lymphoma, 1995, 16, 307-318. | 0.6 | 12 |
| 75 | FICTION-TSA analysis of the B-cell compartment in myeloma shows no significant expansion of myeloma precursor cells. British Journal of Haematology, 1999, 106, 40-46. | 1.2 | 12 |
| 76 | Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study. Lancet Haematology, 2017, 4, e334-e340. | 2.2 | 12 |
| 77 | Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia, 2019, 33, 1953-1963. | 3.3 | 12 |
| 78 | Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. British Journal of Haematology, 2007, 139, 845-848. | 1.2 | 11 |
| 79 | Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 211-213. | 0.2 | 11 |
| 80 | Prevalence and characteristics of monoclonal B-cell lymphocytosis (MBL) in healthy individuals and the relationship with clinical disease. Journal of Biological Regulators and Homeostatic Agents, 2004, 18, 155-60. | 0.7 | 11 |
| 81 | Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. Oncogenesis, 2019, 8, 32. | 2.1 | 10 |
| 82 | Controversies surrounding the clonogenic origin of multiple myeloma. British Journal of Haematology, 2000, 110, 240-241. | 1.2 | 10 |
| 83 | Assessing minimal residual disease in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2008, 3, 47-53. | 1.2 | 9 |
| 84 | Final Report of the UKCLLO2 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).. Blood, 2006, 108, 34-34. | 0.6 | 9 |
| 85 | CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. Haematologica, 2006, 91, 1577-8. | 1.7 | 9 |
| 86 | Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection. Cytometry Part B - Clinical Cytometry, 2010, 78B, S4-9. | 0.7 | 7 |
| 87 | Circulating primitive stem cells in paroxysmal nocturnal hemoglobinuria (PNH) are predominantly normal in phenotype but granulocyte colony-stimulating factor treatment mobilizes mainly PNH stem cells. Blood, 1998, 91, 4504-8. | 0.6 | 7 |
| 88 | Is MRD eradication a desirable goal in CLL?. Best Practice and Research in Clinical Haematology, 2010, 23, 97-107. | 0.7 | 6 |
| 89 | Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as "Unmutated" Have the Greatest Clonal Diversity.. Blood, 2006, 108, 30-30. | 0.6 | 6 |
| 90 | The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells. Blood, 2005, 105, 4895-4896. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Demonstration of a Germinal Center Immunophenotype in Lymphomas by Immunocytochemistry and Flow Cytometry. , 2005, 115, 065-092. | | 5 |
| 92 | GA101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials, 2017, 18, 353. | 0.7 | 5 |
| 93 | Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. BMJ Open, 2021, 11, e041296. | 0.8 | 5 |
| 94 | Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Therapeutic Endpoint for Relapsed CLL.. Blood, 2007, 110, 3114-3114. | 0.6 | 5 |
| 95 | Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia, 2022, 36, 271-274. | 3.3 | 4 |
| 96 | International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL.. Blood, 2004, 104, 15-15. | 0.6 | 4 |
| 97 | Monoclonal B-cell lymphocytosis: Good news for patients and CLL investigators. Leukemia and Lymphoma, 2007, 48, 1057-1058. | 0.6 | 3 |
| 98 | Laboratory Diagnosis of Chronic Lymphocytic Leukaemia. Hematologic Malignancies, 2019, , 21-35. | 0.2 | 3 |
| 99 | Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). Blood, 2010, 116, 922-922. | 0.6 | 3 |
| 100 | Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure. Blood, 2020, 136, 27-28. | 0.6 | 2 |
| 101 | Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 2016, 17, 456. | 0.7 | 1 |
| 102 | Highly selective <sc>SYK</sc> inhibitor, <sc>GSK</sc>143, abrogates survival signals in chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 182, 927-930. | 1.2 | 1 |
| 103 | COSMIC, chemotherapy plus ofatumumab at standard or megaâ€dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology, 2021, 194, 646-650. | 1.2 | 1 |
| 104 | The Prognostic Significance of Phenotypically â€Normalâ€™ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. Blood, 2014, 124, 2073-2073. | 0.6 | 1 |
| 105 | Minimal residual disease detection in myeloma: no more molecular remissions?. Haematologica, 2005, 90, 1300B. | 1.7 | 1 |
| 106 | P245â€Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogrenâ€™s Syndrome. Rheumatology, 2022, 61, . | 0.9 | 1 |
| 107 | Histopathology, Morphology and Immunophenotyping of CLL. , 2013, , 71-89. | | 0 |
| 108 | Reply to M. Roschewski et al. Journal of Clinical Oncology, 2014, 32, 476-477. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Etiology of CLL. , 2008, , 69-89. | | 0 |
| 110 | OA13â€fComprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. Rheumatology, 2022, 61, . | 0.9 | 0 |